Diebold Nixdorf, Incorporated (DBD) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 13 analysts19.3% Below Target
DBD trades 19.3% below Wall Street's consensus target of $100.00.
Current Price$83.81
Average Target$100.00
Low$100.00
Median$100.00
High$100.00
Analyst Target Range
Forward P/E15.3x
(Fair)
PEG Ratio—
Implied Growth+78.8%
(High Growth)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes DBD achieves its forward estimates and maintains a stable P/E multiple of 15.3x. This scenario reflects the blended consensus of 13 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
DBD Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Diebold Nixdorf, Incorporated (DBD) has a Wall Street consensus price target of $100.00, based on estimates from 13 covering analysts. With the stock currently trading at $83.81, this represents a potential upside of +19.3%. The company has a market capitalization of $2.92B.
Analyst price targets range from a low of $100.00 to a high of $100.00, representing a 0% spread in expectations. The median target of $100.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 3 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, DBD trades at a trailing P/E of 33.0x and forward P/E of 15.3x. Analysts expect EPS to grow +78.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $113.85, with bear and bull scenarios of $71.73 and $150.01 respectively. Model confidence stands at 37/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Technology stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+41.0%
Industry Consensus
Avg Forward P/E
14.4x
(Value)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NATLNCR Atleos Corporation | $3.2B | $43.63 | $50.40 | +15.5% | Hold | 10.4x | 4 |
 PAXPatria Investments Limited | $1.8B | $11.37 | $18.00 | +58.3% | Buy | 8.3x | 5 |
 FISFidelity National Information Services, Inc. | $19.7B | $38.21 | $62.88 | +64.6% | Buy | 6.1x | 37 |
 FISVFiserv, Inc. | $25.6B | $47.86 | $71.15 | +48.7% | Buy | 5.9x | 60 |
 MAMastercard Incorporated | $433.6B | $489.79 | $660.43 | +34.8% | Buy | 24.9x | 64 |
 VVisa Inc. | $627.8B | $327.24 | $368.91 | +12.7% | Buy | 24.9x | 61 |
 JKHYJack Henry & Associates, Inc. | $9.1B | $126.23 | $193.75 | +53.5% | Buy | 18.4x | 22 |
 NTAPNetApp, Inc. | $31.6B | $159.71 | $167.00 | +4.6% | Hold | 20.0x | 71 |
 TOSTToast, Inc. | $14.3B | $24.66 | $36.06 | +46.2% | Buy | 18.5x | 30 |
 FOURShift4 Payments, Inc. | $2.7B | $39.42 | $67.62 | +71.5% | Buy | 6.2x | 29 |
DBD — Frequently Asked Questions
Quick answers to the most common questions about buying DBD stock.
What is the DBD stock price target for 2026?
Diebold Nixdorf, Incorporated (DBD) has a consensus 12-month price target of $100, implying 19.3% upside from $83.81. The 13 analysts covering DBD see moderate appreciation potential.
Is DBD a buy, sell, or hold?
DBD has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $100 implies 19.3% upside from current levels.
Is DBD stock overvalued or undervalued?
With a forward P/E of 15.2659x, DBD trades at a relatively low valuation. The consensus target of $100 implies 19.3% appreciation, suggesting meaningful undervaluation.
How high can DBD stock go?
The most bullish Wall Street analyst has a price target of $100 for DBD, while the most conservative target is $100. The consensus of $100 represents the median expectation. Our quantitative valuation model projects a bull case target of $150 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover DBD stock?
DBD is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 5 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the DBD stock forecast?
The 12-month DBD stock forecast based on 13 Wall Street analysts shows a consensus price target of $100, with estimates ranging from $100 (bear case) to $100 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $114, with bear/bull scenarios of $72/$150.
What is DBD's fair value based on fundamentals?
Our quantitative valuation model calculates DBD's fair value at $114 (base case), with a bear case of $72 and bull case of $150. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 37/100.
What is DBD's forward P/E ratio?
DBD trades at a forward P/E ratio of 15.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 33.0x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy DBD stock?
Wall Street analysts are optimistic on DBD, with a "Buy" consensus rating and $100 price target (19.3% upside). 5 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do DBD price targets vary so much?
DBD analyst price targets range from $100 to $100, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $100 consensus represents the middle ground. Our model's $72-$150 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare